Over the last few years, FDA has ramped up its efforts to protect the public from unapproved and potentially dangerous stem cell products, while striving to create a regulatory framework and approach that is as supportive as possible for the advancement of the entire cell and gene therapy (CGT) field.
Upcoming Global Dialogue
IPQ’s virtual meeting schedule through September includes:
IPQ would like to thank our sponsors:
